Celanese Highlights Safe, Effective Polymers for Drug Delivery Devices and Implants at Controlled Release Society Conference
By Business Wire News
By Business Wire News
As a part of the company’s commitment to the health and life sciences industries, Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will participate in the 2016 Controlled Release Society (CRS) Annual Meeting and Exposition, July 17-20 in Seattle, Wash. During the conference, Celanese will highlight VitalDose® ethylene vinyl acetate (EVA), a versatile polymer used in delivering controlled release medications with varying routes of administration including subcutaneous drug delivery implants.
Celanese VitalDose® EVA is a customizable, controlled release material that is meeting the growing needs of the industry as pharmaceutical companies look to create new routes of administration to improve efficacy and increase patient drug compliance.
“There’s more to pharmaceuticals than the drug itself. A reliable and safe method for releasing certain medications is critical to the medications’ effectiveness,” said Kelsey Achenbach, strategic marketing manager for EVA polymers at Celanese. “We have poured decades of experience into engineering VitalDose® EVA so manufacturers have a customizable polymer that gives them the flexibility to develop controlled release devices that can be used for external or subcutaneous applications.”
Celanese engineers designed VitalDose® EVA with properties that allow manufacturers to customize release rate of drugs used in implantable drug delivery devices. This copolymer blends well with other polymers so it can be used alone or with other excipients or additives to achieve the desired release rate. Pharmaceutical companies use VitalDose® EVA in a wide range of drug delivery applications including transdermal, subcutaneous, ocular, intravaginal, intraoral and rectal.
A Celanese pharmaceutical product expert will deliver a poster presentation during the CRS conference that explores how processing techniques can affect pharmaceutical mechanical properties and potentially impede processability.
|Low Temperature Hot Melt Extrusion Processability of Ethylene Vinyl Acetate Copolymers as Pharmaceutical Controlled Release Excipients|
|Monday, July 18, 2016 (see poster #213 for presentation times)|
|Dirk Hair, Technology and Innovation Manager, Product Development, Celanese|
To learn more about Celanese products for health and life sciences, please visit healthcare.celanese.com, and VitalDose® EVA, visit www.VitalDose.com. If you plan to attend the Controlled Release Society Annual Meeting & Exposition, July 17-20 in Seattle, Wash., please stop by the Celanese booth number 409. For more on the conference, visit www.controlledreleasesociety.org/meetings/annual.
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.
All registered trademarks are owned by Celanese International Corporation or its affiliates.
This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or any of its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
Chuck Kyrish, +1 972-443-4574
Media Relations – Global:
W. Travis Jacobsen, +1 972-443-3750
Media Relations Asia (Shanghai):
Helen Zhang, +86 21 3861 9279
Media Relations Europe (Germany):
Jens Kurth, +49(0)69 45009 1574